Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Electrocore Inc (ECOR)

Electrocore Inc (ECOR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 54,968
  • Shares Outstanding, K 8,084
  • Annual Sales, $ 32,030 K
  • Annual Income, $ -13,970 K
  • EBIT $ -13 M
  • EBITDA $ -13 M
  • 60-Month Beta 0.59
  • Price/Sales 1.67
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.58
  • Number of Estimates 2
  • High Estimate $-0.52
  • Low Estimate $-0.65
  • Prior Year $-0.47
  • Growth Rate Est. (year over year) -23.40%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.56 +22.21%
on 03/23/26
8.21 -17.17%
on 03/05/26
-0.97 (-12.48%)
since 03/02/26
3-Month
4.49 +51.44%
on 01/05/26
8.30 -18.07%
on 01/27/26
+2.25 (+49.45%)
since 01/02/26
52-Week
4.16 +63.46%
on 08/11/25
8.64 -21.30%
on 07/09/25
+0.18 (+2.72%)
since 04/02/25

Most Recent Stories

More News
electroCore Announces Publication in Frontiers in Neuroscience Highlighting Benefits of Non-Invasive Vagus Nerve Stimulation in Patients with Mild Traumatic Brain Injury and PTSD

ROCKAWAY, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today the publication of new clinical findings...

ECOR : 6.80 (+3.03%)
electroCore Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

ROCKAWAY, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Seth Abrams...

ECOR : 6.80 (+3.03%)
electroCore Expands Intellectual Property Portfolio

ROCKAWAY, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the issuance of two new U.S. patents...

ECOR : 6.80 (+3.03%)
electroCore Announces Full Year 2025 Financial Results and Organizational Changes

Record f ull year 2025 net sales of $ 32.0 , an increase of 27% over $25.2 million for the full year 2024 driven by 25% annual growth in our U.S. prescription business and 97% increase in general...

ECOR : 6.80 (+3.03%)
electroCore to Participate at the 38th Annual Roth Conference

ROCKAWAY, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a bioelectronic medicine and wellness company, announced today that management will participate in the 38th Annual...

ECOR : 6.80 (+3.03%)
electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2025, Financial Results on Thursday, March 19, 2026

ROCKAWAY, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results...

ECOR : 6.80 (+3.03%)
Acacia Clinics and Vagus Nerve Society Conduct Study Using electroCore’s gammaCore Sapphire for Adjunctive Treatment of Symptoms Associated with Post-Traumatic Stress Disorder (“PTSD”)

ROCKAWAY, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today announced that Acacia Clinics and...

ECOR : 6.80 (+3.03%)
electroCore Provides Preliminary Full-Year 2025 Business Update; Expects ~26% Revenue Growth to ~$31.8–$32.0 Million

Record revenue of approximately $31.8 - $32.0 million for full-year 2025 and approximately $9.0 - $9.2 million for the three months ended December 31, 2025  Revenue growth of approximately 26% over...

ECOR : 6.80 (+3.03%)
TAC-STIM Demonstrates Significant Performance Improvements in Active-Duty United States Air Force Airmen

ROCKAWAY, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today announced the publication of a peer...

ECOR : 6.80 (+3.03%)
electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

ROCKAWAY, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at...

ECOR : 6.80 (+3.03%)

Business Summary

electroCore Inc. is a commercial-stage bioelectronic medicine company. Its current indications are the preventative treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache. electroCore Inc., formerly known as ELECTROCORE LLC, is based in LOS ANGELES, CA....

See More

Key Turning Points

3rd Resistance Point 7.65
2nd Resistance Point 7.26
1st Resistance Point 7.03
Last Price 6.80
1st Support Level 6.41
2nd Support Level 6.02
3rd Support Level 5.79

See More

52-Week High 8.64
Fibonacci 61.8% 6.93
Last Price 6.80
Fibonacci 50% 6.40
Fibonacci 38.2% 5.87
52-Week Low 4.16

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.